Date:8/10/2009

Special charge - - Restructuring benefit (860) 860 (b) - ---- --- - Total costs and expenses 1,076,304 860 1,077,164 Income from operations 86,666 (860) 85,806 Interest and other expenses (1,129) (1,129) ------ ------ Income before income taxes 85,537 (860) 84,677 Provision for income taxes 20,026 12,383 (c) 32,409 Effective tax rate 23.4% 38.3% Minority interest expense 871 871 --- --- Net income $64,640 $(13,243) $51,397 ======= ======== ======= Earnings per common share: -------------------------- Basic $1.16 $0.92 Diluted $1.12 $0.89 Shares used in computing earnings per common share: ------------------- Basic 55,896 55,896 Diluted 57,461 57,461 (a) Represents $15 million in reserves for wind-down costs and bad debt expense related to a client's default on a contract and a related $7.1 million tax benefit. (b) Represents a change in assumptions in restructuring reserves, mainly related to facilities in the U.K. (c) Represents a non-U.S. net tax benefit of $4 million, related in part to
'/>"/>

SOURCE PAREXEL International Corporation Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Related medicine news :

1. PAREXEL International to Present at Bank of America 2008 Smid Cap Conference
2. PAREXEL International to Present at Robert W. Bairds 2008 Growth Stock Conference
3. PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results
4. PAREXEL International to Present at NASDAQ OMX 22nd Investor Program
5. PAREXEL Reports Preliminary Second Quarter Results
6. PAREXEL Announces Date of Second Quarter Fiscal Year 2009 Earnings Release and Conference Call
7. PAREXEL Reports Second Quarter Fiscal Year 2009 Financial Results
8. PAREXEL Consulting Enhances European Regulatory Affairs Capabilities With Appointment of Medical Products Agency Expert Dr. Anders Neil
9. PAREXEL International to Present at Raymond James 30th Annual Institutional Investors and the Barclays Capital Global Healthcare Conferences
10. PAREXEL Announces Date of Third Quarter Fiscal Year 2009 Earnings Release and Conference Call
11. PAREXEL Experts to Address Partnering Best Practices and Innovative Trial Design at Partnerships With CROs Conference